Gene Editing and mRNA Innovators See Promise Despite Stock Slump
-
Intellia Therapeutics is developing gene editing therapies that could be game changers for diseases like ATTR and HAE. Its stock price has dropped 80% despite progress.
-
Intellia's lead therapies could start pivotal trials soon. Competitor CRISPR Therapeutics recently got the first FDA approval for a CRISPR therapy, suggesting regulatory approval is achievable.
-
Moderna stock has fallen 80% from 2021 highs due to lower demand for COVID vaccines, but has promising vaccine candidates targeting RSV, flu, and more.
-
Moderna expects sales growth and profitability by 2025-2026 as new products launch.
-
Both stocks are risky but could rebound if pipelines progress. Aggressive investors may enjoy big returns.